Table 2. Prognostic significance of perioperative parameters for the disease-free survival of surgically resectable non-small-cell lung cancer.
| Characteristics | Entire Cohort | Propensity score matched cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| HR with 95%CI | P value | HR with 95%CI | P value | HR with 95%CI | P value | HR with 95%CI | P value | |
| Age (Years) (Per unit increase) | 1.044 (1.014–1.075) | 0.003 | 1.027 (0.995–1.059) | 0.10 | 1.049 (1.006–1.095) | 0.026 | 1.066 (1.012–1.123) | 0.017 |
| Gender | ||||||||
| Female | Reference | Reference | ||||||
| Male | 1.70 (1.07–2.69) | 0.024 | 1.16 (0.56–2.42) | 0.69 | 2.95 (1.31–6.66) | 0.009 | 2.69 (0.79–9.18) | 0.12 |
| Body mass index (kg/m2) (Per unit increase) | 1.003 (0.934–1.077) | 0.94 | 1.013 (0.914–1.123) | 0.80 | ||||
| Smoking status | ||||||||
| Never | Reference | Reference | ||||||
| Current/former | 1.89 (1.24–2.89) | 0.003 | 1.72 (0.83–3.54) | 0.14 | 2.30 (1.19–4.44) | 0.013 | 1.11 (0.42–2.96) | 0.83 |
| Heavy alcohol consumption | ||||||||
| Never | Reference | Reference | ||||||
| Current/former | 1.20 (0.44–3.27) | 0.72 | 1.18 (0.36–3.84) | 0.78 | ||||
| Respiratory comorbidity | ||||||||
| Absent | Reference | Reference | ||||||
| Present | 1.27 (0.84–1.92) | 0.26 | 1.04 (0.55–1.99) | 0.90 | ||||
| Cardio-cerebrovascular comorbidity | ||||||||
| Absent | Reference | Reference | ||||||
| Present | 1.86 (1.23–2.81) | 0.003 | 1.36 (0.86–2.14) | 0.19 | 1.37 (0.74–2.56) | 0.32 | ||
| Hepatic comorbidity | ||||||||
| Absent | Reference | Reference | ||||||
| Present | 1.14 (0.61–2.15) | 0.68 | 1.19 (0.55–2.58) | 0.65 | ||||
| Diabetes mellitus | ||||||||
| Absent | Reference | Reference | ||||||
| Present | 1.03 (0.55–1.93) | 0.93 | 1.59 (0.67–3.79) | 0.29 | ||||
| Tumor location | ||||||||
| Upper | Reference | Reference | ||||||
| Lower/middle | 1.17 (0.78–1.77) | 0.45 | 0.78 (0.36–1.70) | 0.53 | ||||
| Red blood cell count (1012/L) (Per unit increase) | 0.83 (0.57–1.21) | 0.34 | 0.70 (0.45–1.10) | 0.12 | ||||
| Neutrophil count (109/L) (Per unit increase) | 1.21 (1.11–1.32) | <0.001 | 1.18 (1.07–1.30) | 0.001 | 1.13 (0.97–1.31) | 0.12 | ||
| Lymphocyte count (109/L) (Per unit increase) | 0.57 (0.37–0.87) | 0.009 | 0.56 (0.35–0.91) | 0.019 | 0.37 (0.20–0.69) | 0.002 | 0.44 (0.19–1.00) | 0.050 |
| Serum albumin (g/L) (Per unit increase) | 0.968 (0.910–1.030) | 0.31 | 1.001 (0.909–1.102) | 0.99 | ||||
| Hemoglobin (g/L) (Per unit increase) | 0.990 (0.976–1.004) | 0.15 | 0.982 (0.961–1.003) | 0.088 | 0.978 (0.954–1.002) | 0.076 | ||
| Platelet count (109/L) (Per unit increase) | 0.999 (0.996–1.003) | 0.65 | 0.998 (0.993–1.003) | 0.45 | ||||
| Gamma-glutamyl transpeptidase (IU/L) (Per unit increase) | 1.00 (0.997–1.004) | 0.79 | 1.00 (0.996–1.004) | 0.98 | ||||
| Gamma-glutamyl transpeptidase to platelet ratio | ||||||||
| <0.16 | Reference | Reference | ||||||
| ≥0.16 | 1.88 (1.24–2.83) | 0.003 | 1.59 (1.03–2.47) | 0.040 | 3.30 (1.65–6.59) | 0.001 | 2.62 (1.25–5.48) | 0.011 |
| Histological subtypes | ||||||||
| Adenocarcinoma | Reference | Reference | ||||||
| Squamous cell carcinoma | 1.51 (0.96–2.37) | 0.072 | 1.36 (0.79–2.34) | 0.26 | 1.25 (0.63–2.49) | 0.53 | ||
| Differentiation grade | ||||||||
| Moderate/poor | Reference | Reference | ||||||
| Well | 0.63 (0.40–0.99) | 0.045 | 0.89 (0.52–1.51) | 0.65 | 0.66 (0.34–1.28) | 0.22 | ||
| Tumor invasion (T-stage) | ||||||||
| T1 | Reference | Reference | ||||||
| T2-3 | 2.12 (1.36–3.30) | 0.001 | 1.47 (0.91–2.39) | 0.12 | 1.55 (0.81–2.96) | 0.18 | ||
| Lymph node metastasis (N-stage) | ||||||||
| N0 | Reference | Reference | ||||||
| N1 | 4.25 (2.80–6.44) | <0.001 | 4.37 (2.82–6.77) | <0.001 | 7.37 (3.92–13.87) | <0.001 | 8.57 (4.08–18.01) | <0.001 |
| Any Clavien-Dindo Grade ≥2 complication | ||||||||
| Absent | Reference | Reference | ||||||
| Present | 1.32 (0.85–2.03) | 0.21 | 1.04 (0.52–2.08) | 0.90 | ||||
CI: confidence interval; HR: hazard ratio